Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis
NCT ID: NCT00979615
Last Updated: 2011-05-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
129 participants
INTERVENTIONAL
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid
NCT00845195
Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
NCT00772304
Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
NCT00794144
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
NCT00789555
Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
NCT01470053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Olopatadine HCL Nasal Spray, 0.6%
Olopatadine HCL (Patanase) Nasal Spray, 0.6%
2 sprays/ nostril BID
2
Azelastine HCl Nasal Spray, 137 mcg
Azelastine HCl (Astelin) Nasal Spray, 137 mcg
2 sprays/ nostril BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olopatadine HCL (Patanase) Nasal Spray, 0.6%
2 sprays/ nostril BID
Azelastine HCl (Astelin) Nasal Spray, 137 mcg
2 sprays/ nostril BID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Negative skin tests to a panel of allergens and positive histamine test within last 2 years
* History of symptoms related to defined VMR triggers
Exclusion Criteria
* Bacterial or viral infection within 14 days of first visit. Diagnosis of acute sinusitis within 30 days of first visit
* Chronic use of drugs that can cause rhinitis
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alcon Research Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMA-09-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.